The future of oligonucleotide analysis, from short synthetic DNA to mRNA sequencing
Oligonucleotides have been gaining considerable interest over the last few years with the advent of gene therapy and mRNA vaccines. In addition, the advances in lipid nano particles and viral vectors for the transport of oligonucleotide therapies has increased the popularity and need for analysis of oligonucleotides. The size of the linear chain can vary from a 15mer synthetic oligonucleotide to over 5,000nt bases with mRNA. They can be used in single or double stranded form and include many modifications to help with the stability of the therapeutic. High-throughput synthetic oligonucleotide analysis is discussed with reference to quantitation and adduct removal. We also discuss the first example of a complete workflow for mRNA sequencing.
Learning Points:
- High-throughput synthetic oligonucleotide characterization
- Direct mRNA sequencing by LC/HRMS
- Software advances in oligonucleotide characterization
Who should attend:
- Analysts in synthetic oligonucleotide laboratories
- Vaccine development and production laboratories
- Universities and R&D development laboratories involved in Oligonucleotide research
Presenter: Ken Cook (EU Pharma/Biopharma expert support group team leader, Thermo Fisher Scientific)
Ken Cook started as a university lecturer in Protein Biochemistry at the University of Newcastle upon Tyne before moving to industry. Now with over 33 years’ experience with Thermo Fisher Scientific. Ken supports development of Bio-Pharmaceutical applications to characterize protein and oligonucleotide based bio-therapeutics. This involves ongoing collaborations with the Biopharmaceutical industry and academia. Methods for the characterization of therapeutic proteins include peptide mapping, Intact analysis, including novel native intact coupling to MS, Glycans, aggregates and on-line process monitoring.
Presenter: Andrew Williamson (EU Pharma/Biopharma expert support group, Thermo Fisher Scientific)
Andrew Williamson is a Biopharma Sales Expert at Thermo Scientific. Prior to this role, Andrew worked as a proteomics specialist within Thermo Scientific having moved from the University of Manchester where he worked and managed a proteomics laboratory at the Christie Hospital site. During this time Andrew worked on the proteomic analysis of a number of oncology based projects looking into key indicators of response to treatment and biomarker discovery. During this time Andrew also collaborated globally analysing a variety of stem cell and cancer samples, including murine, human and induced pluripotent stem cells.
